Belle Mead, NJ, United States of America

John N Feder

This inventor holds 67 USPTO granted patents and 4 published patent applications, plus 4 CIPO patents and 4 EPO patents, primarily in G-Protein Coupled Receptors. Top assignees: Bristol-Myers Squibb Compnay, Bio-Rad Laboratories, Inc., Mercator Genetics, Inc.. Active years: 1998-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John N Feder. Retrieved from https://idiyas.com/inventor/john-n-feder

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 67 (Patent Applications = 4)

% Patents Active = 76.1

CIPO Patents = 4

EPO Patents = 4 (Patent Applications = 2)

Average Co-Inventor Count = 4.2

ph-index = 12

Forward Citations = 455(Granted Patents)

Forward Citations (Not Self Cited) = 381(Dec 10, 2025)

Location History:

San Callos, CA (US) (1998)
Mount View, CA (US) (1998)
Belle Meade, NJ (US) (2007)
San Carlos, CA (US) (1999 - 2008)
Mountain View, CA (US) (1998 - 2012)
Belle Mead, NJ (US) (2003 - 2013)

Company Filing History:

40 out of 3,745

Bristol-Myers Squibb Compnay

patents

14 out of 1,072

Bio-Rad Laboratories, Inc.

patents

5 out of 6

Mercator Genetics, Inc.

patents

4. 4 out of 4,632

California Institute of Technology

patents

5. 3 out of 41

Bristol Meyers Squibb Company

Brilstol-Myers Squibb

patent

8. 1 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2013

Loading Chart...

Areas of Expertise:

Polynucleotides

G-Protein Coupled Receptors

Cancer Diagnostics

PCSK9 Variants

Iron Overload Diseases

Crohn's Disease

Histone Deacetylase

TRP Channel Family

Tumor Detection

Antibodies

Genotype Determination

Peptides

67 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8354264 - Polynucleotides encoding novel PCSK9 variants (2013-01-15),

2. 8257927 - Hereditary hemochromatosis gene (2012-09-04),

3. 8124729 - Splice variants of human G-protein coupled receptor HGPRBMY29 (HGPRMBY29SV2) (2012-02-28),

4. 8105804 - Polynucleotides encoding novel PCSK9 variants (2012-01-31),

5. 7998680 - Determining genotype of a polymorphic site in the hereditary hemochromatosis gene (2011-08-16),

6. 7846706 - PCSK9 polypeptides (2010-12-07),

7. 7767418 - Polynucleotide encoding a novel TRP channel family member, LTRPC3, and splice variants thereof (2010-08-03),

8. 7741025 - Method of diagnosing lung cancer using BGS42 (2010-06-22),

9. 7713699 - Methods of diagnosing colon adenocarcinoma using mRNA encoding the human g-protein coupled receptor, HGPRBMY23 (2010-05-11),

10. 7705134 - Antibodies that bind to BGS-4 (2010-04-27),

11. 7635758 - Antibodies directed to G-protein coupled receptor HGPRBMY29sv1 (2009-12-22),

12. 7579169 - Hereditary hemochromatosis gene (2009-08-25),

13. 7531310 - Methods of diagnosing Crohn's disease by measuring expression level of RNA encoding human G-protein coupled receptor, HGPRBMY11 (2009-05-12),

14. 7521044 - Human histone deacetylase, HDAC9c (2009-04-21),

15. 7517652 - Methods of diagnosing tumors using the G-protein coupled receptor (GPCR), RAI-3 (2009-04-14),

Title: Innovations and Contributions of John N. Feder in Biotechnology

Introduction

John N. Feder, based in Belle Mead, NJ, has made significant contributions to the field of biotechnology, holding an impressive portfolio of 47 patents. His work primarily focuses on novel polynucleotides and their applications in diagnosing and treating various diseases.

Latest Patents

Among his latest patents, Feder has developed innovative polynucleotides encoding novel PCSK9 variants. This invention provides essential tools such as vectors, host cells, antibodies, and methods for producing PCSK9b and PCSK9c polypeptides. The invention further extends to diagnostic and therapeutic methods utilizing these polypeptides for various disease-related applications. Another noteworthy patent involves splice variants of the human G-protein coupled receptor HGPRBMY29. This patent also includes a variety of polynucleotides and polypeptides, which are crucial for the diagnosis, treatment, and prevention of related disorders.

Career Highlights

Feder has played a pivotal role in prominent organizations, including Bristol-Myers Squibb Company. His contributions at this leading pharmaceutical corporation have significantly advanced research in biotechnology and drug development.

Collaborations

Throughout his career, Feder has collaborated with talented individuals like Chandra S. Ramanathan and Gabriel A. Mintier. These partnerships have fostered innovation and have been instrumental in achieving breakthroughs in their respective fields.

Conclusion

John N. Feder's extensive patent portfolio and collaborative efforts highlight his role as an influential figure in biotechnology. His inventions not only demonstrate his creativity and expertise but also pave the way for advancements in medical research and treatment methodologies. His ongoing contributions continue to inspire future innovations in the field.

Profile summary based on public USPTO records.